Click here to get full coverage on If You Invested $1,000 in Scienture Holdings, Inc (SCNX) - stocktitan.net

If You Invested $1,000 in Scienture Holdings, Inc (SCNX)  stocktitan.net

If You Invested $1,000 in Scienture Holdings, Inc (SCNX) - stocktitan.net

Click here to get full coverage on AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™  Intellectia AI

AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

Click here to get full coverage on Market Movers | Winners: ELAB, BFRG, ASTC | Losers: SCNX, ORGN, HWH - Trefis

Market Movers | Winners: ELAB, BFRG, ASTC | Losers: SCNX, ORGN, HWH  Trefis

Market Movers | Winners: ELAB, BFRG, ASTC | Losers: SCNX, ORGN, HWH - Trefis

Click here to get full coverage on Scienture Holdings: Q4 Earnings Snapshot - KTVB

Scienture Holdings: Q4 Earnings Snapshot  KTVB

Scienture Holdings: Q4 Earnings Snapshot - KTVB

Click here to get full coverage on Why Is Scienture Holdings Stock (SCNX) Up Today? - TipRanks

Why Is Scienture Holdings Stock (SCNX) Up Today?  TipRanks

Why Is Scienture Holdings Stock (SCNX) Up Today? - TipRanks

Click here to get full coverage on Scienture’s blood pressure drug drove 216% growth; overdose spray up next - stocktitan.net

Scienture’s blood pressure drug drove 216% growth; overdose spray up next  stocktitan.net

Scienture’s blood pressure drug drove 216% growth; overdose spray up next - stocktitan.net

Click here to get full coverage on Scienture Holdings 10-K: $0.43M Revenue, $(2.70) EPS — ARBLI™ Launch Drives Growth - TradingView

Scienture Holdings 10-K: $0.43M Revenue, $(2.70) EPS — ARBLI™ Launch Drives Growth  TradingView

Scienture Holdings 10-K: $0.43M Revenue, $(2.70) EPS — ARBLI™ Launch Drives Growth - TradingView

Click here to get full coverage on Struggling SCNX Faces Financial Turbulence Amid Market Shocks - StocksToTrade

Struggling SCNX Faces Financial Turbulence Amid Market Shocks  StocksToTrade

Struggling SCNX Faces Financial Turbulence Amid Market Shocks - StocksToTrade

Click here to get full coverage on SCNX PE Ratio & Valuation, Is SCNX Overvalued - Intellectia AI

SCNX PE Ratio & Valuation, Is SCNX Overvalued  Intellectia AI

SCNX PE Ratio & Valuation, Is SCNX Overvalued - Intellectia AI

Click here to get full coverage on 3/30/2026 Market Update - Winners: ELAB, BFRG, ASTC - Losers: SCNX, ORGN, HWH - S&P 500: -0.4% - Trefis

3/30/2026 Market Update - Winners: ELAB, BFRG, ASTC - Losers: SCNX, ORGN, HWH - S&P 500: -0.4%  Trefis

3/30/2026 Market Update - Winners: ELAB, BFRG, ASTC - Losers: SCNX, ORGN, HWH - S&P 500: -0.4% - Trefis

Click here to get full coverage on High-dose overdose spray REZENOPY set to reach 5,000 US care sites - stocktitan.net

High-dose overdose spray REZENOPY set to reach 5,000 US care sites  stocktitan.net

High-dose overdose spray REZENOPY set to reach 5,000 US care sites - stocktitan.net

Click here to get full coverage on Scienture Holdings (NASDAQ: SCNX) outlines CNS, CVS drug launches and pipeline - stocktitan.net

Scienture Holdings (NASDAQ: SCNX) outlines CNS, CVS drug launches and pipeline  stocktitan.net

Scienture Holdings (NASDAQ: SCNX) outlines CNS, CVS drug launches and pipeline - stocktitan.net

Click here to get full coverage on Scienture Holdings (SCNX) Co-CEO granted 500,000 restricted shares - stocktitan.net

Scienture Holdings (SCNX) Co-CEO granted 500,000 restricted shares  stocktitan.net

Scienture Holdings (SCNX) Co-CEO granted 500,000 restricted shares - stocktitan.net

Click here to get full coverage on Scienture (SCNX) Co-CEO adds stock grants and converts preferred into common - stocktitan.net

Scienture (SCNX) Co-CEO adds stock grants and converts preferred into common  stocktitan.net

Scienture (SCNX) Co-CEO adds stock grants and converts preferred into common - stocktitan.net

Click here to get full coverage on Latest SCNX News - SCIENTURE Reports Year End 2025 Financial R... - stocktitan.net

Latest SCNX News - SCIENTURE Reports Year End 2025 Financial R...  stocktitan.net

Latest SCNX News - SCIENTURE Reports Year End 2025 Financial R... - stocktitan.net

Click here to get full coverage on New patent backs 10 mg naloxone spray for life-saving overdose treatment - stocktitan.net

New patent backs 10 mg naloxone spray for life-saving overdose treatment  stocktitan.net

New patent backs 10 mg naloxone spray for life-saving overdose treatment - stocktitan.net

Click here to get full coverage on New 10 mg overdose nasal spray set to reach U.S. market in 2026 - stocktitan.net

New 10 mg overdose nasal spray set to reach U.S. market in 2026  stocktitan.net

New 10 mg overdose nasal spray set to reach U.S. market in 2026 - stocktitan.net

Click here to get full coverage on Scienture (NASDAQ: SCNX) taps BlinkRx to launch Arbli, first ready-to-use losartan oral suspension in Q1 2026 - stocktitan.net

Scienture (NASDAQ: SCNX) taps BlinkRx to launch Arbli, first ready-to-use losartan oral suspension in Q1 2026  stocktitan.net

Scienture (NASDAQ: SCNX) taps BlinkRx to launch Arbli, first ready-to-use losartan oral suspension in Q1 2026 - stocktitan.net

Click here to get full coverage on Scienture (NASDAQ: SCNX) launches Arbli, FDA-approved liquid losartan; revenue hits $590K - stocktitan.net

Scienture (NASDAQ: SCNX) launches Arbli, FDA-approved liquid losartan; revenue hits $590K  stocktitan.net

Scienture (NASDAQ: SCNX) launches Arbli, FDA-approved liquid losartan; revenue hits $590K - stocktitan.net

Click here to get full coverage on Scienture (NASDAQ: SCNX) adds Arbli to health plan formularies, access for 100M+ lives - stocktitan.net

Scienture (NASDAQ: SCNX) adds Arbli to health plan formularies, access for 100M+ lives  stocktitan.net

Scienture (NASDAQ: SCNX) adds Arbli to health plan formularies, access for 100M+ lives - stocktitan.net

Click here to get full coverage on Scienture Reports Year End 2025 Financial Results And Provides Business Update - TradingView

Scienture Reports Year End 2025 Financial Results And Provides Business Update  TradingView

Scienture Reports Year End 2025 Financial Results And Provides Business Update - TradingView

Click here to get full coverage on Scienture (NASDAQ: SCNX) begins Arbli sales; $256M losartan market, 2,500 institutions - stocktitan.net

Scienture (NASDAQ: SCNX) begins Arbli sales; $256M losartan market, 2,500 institutions  stocktitan.net

Scienture (NASDAQ: SCNX) begins Arbli sales; $256M losartan market, 2,500 institutions - stocktitan.net

Click here to get full coverage on SCNX Financials: Income Statement, Balance Sheet & Cash Flow - stocktitan.net

SCNX Financials: Income Statement, Balance Sheet & Cash Flow  stocktitan.net

SCNX Financials: Income Statement, Balance Sheet & Cash Flow - stocktitan.net

Click here to get full coverage on Scienture Launches First FDA-Approved Liquid Losartan | SCNX Stock News - stocktitan.net

Scienture Launches First FDA-Approved Liquid Losartan | SCNX Stock News  stocktitan.net

Scienture Launches First FDA-Approved Liquid Losartan | SCNX Stock News - stocktitan.net

Click here to get full coverage on Pharma Stock SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) Makes Nasdaq Top Gainer on News of Commercial Sales and Fulfillment of First Orders for Arbli - investorideas.com

Pharma Stock SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) Makes Nasdaq Top Gainer on News of Commercial Sales and Fulfillment of First Orders for Arbli  investorideas.com

Pharma Stock SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) Makes Nasdaq Top Gainer on News of Commercial Sales and Fulfillment of First Orders for Arbli - investorideas.com

Click here to get full coverage on $2.4861 conversion: SCIENTURE converts debentures to equity, discharges debt and releases liens - stocktitan.net

$2.4861 conversion: SCIENTURE converts debentures to equity, discharges debt and releases liens  stocktitan.net

$2.4861 conversion: SCIENTURE converts debentures to equity, discharges debt and releases liens - stocktitan.net

Click here to get full coverage on Why Is Scienture Stock Gaining Today? - Scienture Holdings (NASDAQ:SCNX) - Benzinga

Why Is Scienture Stock Gaining Today? - Scienture Holdings (NASDAQ:SCNX)  Benzinga

Why Is Scienture Stock Gaining Today? - Scienture Holdings (NASDAQ:SCNX) - Benzinga

Click here to get full coverage on SCNX Stock Climbs Amid Strategic Partnership Talks - timothysykes.com

SCNX Stock Climbs Amid Strategic Partnership Talks  timothysykes.com

SCNX Stock Climbs Amid Strategic Partnership Talks - timothysykes.com

Click here to get full coverage on SCNX Shares Soar After Milestone Achievement - StocksToTrade

SCNX Shares Soar After Milestone Achievement  StocksToTrade

SCNX Shares Soar After Milestone Achievement - StocksToTrade

Click here to get full coverage on EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025 - Benzinga

EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025  Benzinga

EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025 - Benzinga

Click here to get full coverage on Why Did Scienture Stock (SCNX) Soar 45% Today? - TipRanks

Why Did Scienture Stock (SCNX) Soar 45% Today?  TipRanks

Why Did Scienture Stock (SCNX) Soar 45% Today? - TipRanks

Click here to get full coverage on Unexpected Surge: SCNX Defies Predictions - StocksToTrade

Unexpected Surge: SCNX Defies Predictions  StocksToTrade

Unexpected Surge: SCNX Defies Predictions - StocksToTrade

Click here to get full coverage on First FDA-approved liquid losartan hits distribution centers as Scienture targets $276M market - stocktitan.net

First FDA-approved liquid losartan hits distribution centers as Scienture targets $276M market  stocktitan.net

First FDA-approved liquid losartan hits distribution centers as Scienture targets $276M market - stocktitan.net

Click here to get full coverage on SCNX Stocks Surge: Unexpected Gains Require Attention - timothysykes.com

SCNX Stocks Surge: Unexpected Gains Require Attention  timothysykes.com

SCNX Stocks Surge: Unexpected Gains Require Attention - timothysykes.com

Click here to get full coverage on Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum? - Benzinga

Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?  Benzinga

Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum? - Benzinga

Click here to get full coverage on USTDA Supports SCNX-3 Feasibility with APTelecom - SubTel Forum

USTDA Supports SCNX-3 Feasibility with APTelecom  SubTel Forum

USTDA Supports SCNX-3 Feasibility with APTelecom - SubTel Forum

Click here to get full coverage on Scienture Holdings stockholders approve reverse split and equity plan expansion - investing.com

Scienture Holdings stockholders approve reverse split and equity plan expansion  investing.com

Scienture Holdings stockholders approve reverse split and equity plan expansion - investing.com

Click here to get full coverage on Scienture (SCNX) Advances with REZENOPY Nasal Spray Launch - GuruFocus

Scienture (SCNX) Advances with REZENOPY Nasal Spray Launch  GuruFocus

Scienture (SCNX) Advances with REZENOPY Nasal Spray Launch - GuruFocus

Click here to get full coverage on Is Scienture Holdings (NASDAQ:SCNX) Using Debt Sensibly? - simplywall.st

Is Scienture Holdings (NASDAQ:SCNX) Using Debt Sensibly?  simplywall.st

Is Scienture Holdings (NASDAQ:SCNX) Using Debt Sensibly? - simplywall.st

Click here to get full coverage on Scienture Bets Big On Liquid Drugs And Nasal Sprays - Finimize

Scienture Bets Big On Liquid Drugs And Nasal Sprays  Finimize

Scienture Bets Big On Liquid Drugs And Nasal Sprays - Finimize

Click here to get full coverage on EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction - Yahoo Finance

EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction  Yahoo Finance

EXCLUSIVE: Scienture Delivers Q3 Revenue Jump With Arbli Sales And Debt Reduction - Yahoo Finance

Click here to get full coverage on INTC, SCNX, F, DECK, SMCI: 5 Trending Stocks Today - Intel (NASDAQ:INTC) - Benzinga

INTC, SCNX, F, DECK, SMCI: 5 Trending Stocks Today - Intel (NASDAQ:INTC)  Benzinga

INTC, SCNX, F, DECK, SMCI: 5 Trending Stocks Today - Intel (NASDAQ:INTC) - Benzinga

Click here to get full coverage on SCNX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

SCNX Earning Date, Earning Analysis and Earning Prediction  Intellectia AI

SCNX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Click here to get full coverage on SCNX Stock Surges Amid New Financial Disclosure Insights - StocksToTrade

SCNX Stock Surges Amid New Financial Disclosure Insights  StocksToTrade

SCNX Stock Surges Amid New Financial Disclosure Insights - StocksToTrade

Click here to get full coverage on Why Is Scienture Stock Rising Today? - Stocktwits

Why Is Scienture Stock Rising Today?  Stocktwits

Why Is Scienture Stock Rising Today? - Stocktwits

Click here to get full coverage on Scienture Holdings Faces Nasdaq Non-Compliance Notice - The Globe and Mail

Scienture Holdings Faces Nasdaq Non-Compliance Notice  The Globe and Mail

Scienture Holdings Faces Nasdaq Non-Compliance Notice - The Globe and Mail

Click here to get full coverage on Scienture stock soars as first FDA-approved losartan oral suspension hits market - investing.com

Scienture stock soars as first FDA-approved losartan oral suspension hits market  investing.com

Scienture stock soars as first FDA-approved losartan oral suspension hits market - investing.com

Click here to get full coverage on Scienture receives patent for high-dose naloxone nasal spray - investing.com

Scienture receives patent for high-dose naloxone nasal spray  investing.com

Scienture receives patent for high-dose naloxone nasal spray - investing.com

Click here to get full coverage on Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next? - TechStock²

Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next?  TechStock²

Scienture Shares Skyrocket 350% on FDA-Approved Drug Launch – What’s Next? - TechStock²

Click here to get full coverage on EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emerge - Benzinga

EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emerge  Benzinga

EXCLUSIVE: Penny Stock Scienture's Partner Secures US Patent For Highest Dosage Naloxone Spray For Emerge - Benzinga

Click here to get full coverage on Maxim Group Initiates Coverage on Scienture (NASDAQ:SCNX) - National Today

Maxim Group Initiates Coverage on Scienture (NASDAQ:SCNX)  National Today

Maxim Group Initiates Coverage on Scienture (NASDAQ:SCNX) - National Today

Click here to get full coverage on EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients - Benzinga

EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients  Benzinga

EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients - Benzinga

Click here to get full coverage on Scienture stock plummets after announcing $3.9 million registered offering - investing.com

Scienture stock plummets after announcing $3.9 million registered offering  investing.com

Scienture stock plummets after announcing $3.9 million registered offering - investing.com

Click here to get full coverage on Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last? - TechStock²

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?  TechStock²

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last? - TechStock²

Click here to get full coverage on EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives - Benzinga

EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives  Benzinga

EXCLUSIVE: Scienture Expands Access To Arbli Losartan Oral Suspension With Addition To Formularies Covering 100 Million Lives - Benzinga

Click here to get full coverage on SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - The Globe and Mail

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions  The Globe and Mail

SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - The Globe and Mail

Click here to get full coverage on Scienture Holdings Second Quarter 2025 Earnings: US$0.47 loss per share (vs US$1.16 loss in 2Q 2024) - Yahoo Finance

Scienture Holdings Second Quarter 2025 Earnings: US$0.47 loss per share (vs US$1.16 loss in 2Q 2024)  Yahoo Finance

Scienture Holdings Second Quarter 2025 Earnings: US$0.47 loss per share (vs US$1.16 loss in 2Q 2024) - Yahoo Finance

Click here to get full coverage on Scienture’s Arbli added to national formularies, expanding access - investing.com

Scienture’s Arbli added to national formularies, expanding access  investing.com

Scienture’s Arbli added to national formularies, expanding access - investing.com

Click here to get full coverage on Scienture reports progress on ARBLI, confirms REZENOPY launch - investing.com

Scienture reports progress on ARBLI, confirms REZENOPY launch  investing.com

Scienture reports progress on ARBLI, confirms REZENOPY launch - investing.com

Click here to get full coverage on Scienture (SCNX) Launches Arbli Oral Suspension, Boosting Market Presence - GuruFocus

Scienture (SCNX) Launches Arbli Oral Suspension, Boosting Market Presence  GuruFocus

Scienture (SCNX) Launches Arbli Oral Suspension, Boosting Market Presence - GuruFocus

Click here to get full coverage on SCNX Reaches Agreement with Arena to Settle Convertible Debentures - GuruFocus

SCNX Reaches Agreement with Arena to Settle Convertible Debentures  GuruFocus

SCNX Reaches Agreement with Arena to Settle Convertible Debentures - GuruFocus

Click here to get full coverage on EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients - Yahoo Finance

EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients  Yahoo Finance

EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients - Yahoo Finance

Click here to get full coverage on 12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session  Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Click here to get full coverage on Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - stocktitan.net

Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets  stocktitan.net

Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - stocktitan.net

Click here to get full coverage on Scienture (SCNX) Stock Jumps 355% Following FDA-Approved Arbli Launch - Blockonomi

Scienture (SCNX) Stock Jumps 355% Following FDA-Approved Arbli Launch  Blockonomi

Scienture (SCNX) Stock Jumps 355% Following FDA-Approved Arbli Launch - Blockonomi

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Scienture to launch high-strength naloxone nasal spray in Q2 2026 - investing.com

Scienture to launch high-strength naloxone nasal spray in Q2 2026  investing.com

SCNX

Price Chart

Key Statistics

Technicals

About SCNX

Latest News

If You Invested $1,000 in Scienture Holdings, Inc (SCNX) - stocktitan.net

AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI

Market Movers | Winners: ELAB, BFRG, ASTC | Losers: SCNX, ORGN, HWH - Trefis

Advanced Charts

Top Gainers

Top Losers